A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors

被引：0
|
作者：
Papadopoulos, K. [1 ]
Tolcher, A. [1 ]
Kittaneh, M. [2 ]
Patniak, A. [1 ]
Rasco, D. [1 ]
Chambers, G. [1 ]
Newth, G. [2 ]
Savage, R. [3 ]
Hall, T. [3 ]
Schwartz, B. [3 ]
Kazakin, J. [3 ]
LoRusso, P. [2 ]
机构：
[1] South Texas Accelerated Res Therapeut, Med Oncol, San Antonio, TX USA
[2] Karmanos Canc Inst, Ctr Translat Therapeut, Detroit, MI USA
[3] ArQule Inc, Clin Dev, Woburn, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70515-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
389
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [21] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [22] First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
    Saleh, M.
    Papadpoulos, K.
    Arabnia, A.
    Patnaik, A.
    Stein, R. M.
    Chai, F.
    Lamar, M.
    Savage, R.
    Abbadessa, G.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 104 - 104
  • [23] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [25] First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors
    Li, Wei
    Wang, Yongsheng
    Xiong, Anwen
    Gao, Ge
    Song, Zhengbo
    Zhang, Yiping
    Huang, Dingzhi
    Ye, Feng
    Wang, Qiming
    Li, Zhihui
    Liu, Jiaye
    Xu, Chunwei
    Sun, Yinghui
    Liu, Xijie
    Zhou, Fei
    Zhou, Caicun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [26] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
    Eskens, F.
    Opdam, F.
    Gort, E.
    Gelderblom, H.
    Prestegarden, L.
    Pico-Navarro, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
  • [27] First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. -C.
    Balandraud, S.
    Brendel, K.
    Cattan, V.
    Jacquet-Bescond, A.
    Busto, N. Lopez
    Malasse, S.
    Marfai, L.
    Pauly, J.
    Prudkin, L.
    Azaro, A.
    Rodon, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 37 - 37
  • [28] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [29] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Pant, Shubham
    Burris, Howard A., III
    Moore, Kathleen
    Bendell, Johanna C.
    Kurkjian, Carla
    Jones, Suzanne F.
    Moreno, Ofir
    Kuhn, John G.
    McMeekin, Scott
    Infante, Jeffrey R.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 87 - 93
  • [30] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Shubham Pant
    Howard A. Burris
    Kathleen Moore
    Johanna C. Bendell
    Carla Kurkjian
    Suzanne F. Jones
    Ofir Moreno
    John G. Kuhn
    Scott McMeekin
    Jeffrey R. Infante
    Investigational New Drugs, 2014, 32 : 87 - 93
12345